Navigation Links
Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
Date:11/30/2009

KING OF PRUSSIA, Pa., Nov. 30 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the completion of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. Results of the safety and tolerability dose escalation study in healthy volunteers confirm the safety of this compound in initial clinical testing.

All 30 enrolled subjects completed the study, including those receiving the highest dose of CPSI-2364 (270 mg), approximately 30 times the dose that animal models predict will be effective. The drug was well-tolerated with a low incidence of mostly mild adverse events.

"We have now demonstrated that CPSI-2364, a more soluble salt form of semapimod, is safe in humans at doses well above those required for efficacy," said Dr. Thais Sielecki, Vice President of Preclinical Development at Cytokine PharmaSciences. "We have also established a target dose range that we believe optimizes the therapeutic index for CPSI-2364 for use in our next stage of clinical testing."

A Phase II study in patients with Crohn's disease is planned for early 2010.

About CPSI-2364

CPSI-2364 is a chemically-modified form of the synthetic guanylhydrozone, semapimod. Semapimod has been shown to inhibit the signal transduction pathways that lead to the production of nitric oxide and important pro-inflammatory cytokines, including TNF-alpha, IL-1, IL-6, and IL-8. Semapimod has demonstrated activity in multiple animal models of inflammation and autoimmune disease, proof-of-concept studies that led to human clinical trials. An intravenous formulation of semapimod was shown to have significant anti-inflammatory activity in Phase II clinical trials in Crohn's disease, psoriasis and ERCP-induced pancreatitis. However, that formulation caused dose-limiting local reactions, such as phlebitis. To overcome this problem, the Company developed CPSI-2364, a more soluble salt of semapimod that makes oral dosing possible. Animal models have confirmed the oral activity of CPSI-2364.

About Cytokine PharmaSciences

Cytokine PharmaSciences, Inc. is a specialty pharmaceutical company engaged in developing anti-inflammatory and autoimmune therapeutics. The Company is headquartered in King of Prussia (near Philadelphia), Pennsylvania. A wholly owned subsidiary, Controlled Therapeutics (Scotland) Limited (CT), is located in East Kilbride (near Glasgow). CT develops and manufactures controlled-release drug delivery products and has a strong focus in the area of women's health, including manufacturing the successful cervical ripening product, the Cervidil® vaginal insert (Propess® in Europe and elsewhere). Cytokine PharmaSciences has three products in clinical development and employs 70 people at its locations in the U.S. and Scotland. For more information, please visit the company's websites at www.cytokinepharmasciences.com and www.ctscotland.com.

SOURCE Cytokine PharmaSciences, Inc.


'/>"/>
SOURCE Cytokine PharmaSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Cytokine Announces Oral Efficacy of Anti-Cytokine Semapimod
4. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
5. Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis
6. BD Completes Acquisition of HandyLab, Inc.
7. EDDA Technology Completes CE Mark for IQQA(R)-Liver for Fast Quantitative Volumetry Assessment from Liver MDCT
8. WellTek/MedX Group Completes Major Reorganization
9. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
10. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
11. Cell Biosciences Completes Acquisition of Alpha Innotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins ... the public.Where:  BTF,s Mobile MRI Unit – a ... Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... September 26, 2017 , ... “Sound of My Song”: an intriguing and ... published author, Karmen Worden, a retired teacher with a passion for music and ancestral ... intriguing and inspiring story on loss, living with depression, and finding love through the ...
(Date:9/26/2017)... ... ... Tour Guide”: is the life story of the author and the exciting times this adventurer ... is an adventure tour guide and the subject of the book. , “Quickly slapping ... shocked faces. I played it off as a part of the adventure tour, an “added ...
(Date:9/26/2017)... , ... September 26, 2017 , ... Time out for ... a little boy's newfound understanding that even grownups make mistakes. “Time Out for Daddy” ... United States for her entire life and whose passion for children inspired her to ...
(Date:9/25/2017)... Texas (PRWEB) , ... September 25, 2017 , ... ... VitalBand, the first and only fully programmable fall detection smart watch. VitalBand ... as many critical contacts as you want so help arrives quickly. Plus, ...
(Date:9/25/2017)... Reston, VA (PRWEB) , ... September 25, 2017 ... ... mobile application security, today announced its latest release of SentinelSecure™, version 3.0, will ... website Secure.Systems . This newest version of SentinelSecure™ comes with several new ...
Breaking Medicine News(10 mins):